Non-invasive prediction of forthcoming cirrhosis-related complications

Table 1 Description of prognostic studies assessing non-invasive tools for the prediction of forthcoming cirrhosis-related complications

Ref.	Etiology of liver disease	n	Assessment modality1	Endpoint	AUROC
Kim et al[45]	LC (HBV)	577	LSPS	Esophageal variceal bleeding	0.929
Berzigotti et al[46]	LC (mostly HCV)	117 (T)/56 (V)	LSPS, platelet count, spleen diameter, LS	Esophageal varices	0.882 (T), 0.808 (V)
				Clinically significant portal hypertension	0.918 (T), 0.906 (V)
Masuzaki et al[49]	CLD (HCV)	866	LS	Hepatocellular carcinoma	N/A
Jung et al[33]	LC (HBV)	1130	LS	Hepatocellular carcinoma	N/A
Kim et al[50]	LC (HBV)	217	LS, LSPS	Hepatic decompensation	0.773 (LS); 0.790 (LSPS)
Kim et al[51]	CLD (HBV)	128	LS	Liver-related events	0.772
Chon et al[52]	CLD (HBV)	1126	LS, LSPS,	Hepatocellular carcinoma	0.789 (LS); 0.790 (LSPS)
			ASPRI, P2/MS, FIB-4	Hepatic decompensation	0.820 (LS); 0.848 (LSPS)
Kim et al[53]	CLD (HBV) on antiviral therapy	162	LS	Liver-related events	0.736
Kim et al[54]	LC (HBV) on antiviral therapy	103	LS	Liver-related events	N/A
Singh et al[56]2	CLD (various)	7058	LS	Liver-related events	N/A
Parkes et al[58]	CLD (various)	457	ELF	Liver-related events	0.82
Kim et al[62]	CLD (HBV)	170	ELF	Liver-related events	0.808
Vergniol et al[66]	CLD (HCV)	1457	FT, LS, APRI, FIB-4, LB	Overall survival (5-yr)	0.861 (FT)
de Ledinghen et al[67]	CLD (HBV)	600	FT, LS, APRI, FIB-4, LB	Overall survival (5-yr)	0.82 (FT)
Park et al[68]	CLD (HBV)	151	FT, LS, FT + LS, FT × LS, LB	Liver-related events	0.748 (FT + LS); 0.868 (FT × LS)
Morishita et al[77]3	LC (HCV)	135	ARFI (LS)	Esophageal varices (high-risk)	0.890 (0.868)
Takuma et al[78]3	LC (mostly HCV)	340	ARFI (SS, LS)	Esophageal varices (high-risk)	0.993 (0.930)

¹Bold face denotes main assessment modality;

²Meta-analysis;

³Cross-sectional study. AUROC: Area-under-the-receiver-operating curve; LC: Liver cirrhosis; CLD: Chronic liver disease; HBV: Hepatitis B virus; HCV: Hepatitis C virus; T: Training set; V: Validation set; LSPS: Liver stiffness-spleen diameter to platelet ratio score; LS: Liver stiffness; ASPRI: Age-spleen-platelet ratio index; ELF: European Liver Fibrosis; FT: Fibrotest; APRI: Aspartate aminotransferase to platelet ratio index; ARFI: Acoustic radiation force impulse; SS: Spleen stiffness; N/A: Not available.